The price of Bristol-Myers Squibb Co (NYSE:BMY) shares last traded on Wall Street rose 1.80% to $49.82.
BMY stock price is now -12.58% away from the 50-day moving average and -7.29% away from the 200-day moving average. The market capitalization of the company currently stands at $101.37B.
On April 22, 2025, Cantor Fitzgerald recently initiated its ‘Neutral’ rating on the stock quoting a target price of $55, while ‘Jefferies’ rates the stock as ‘Buy’
In other news, BOERNER CHRISTOPHER S., Chief Executive Officer bought 2,000 shares of the company’s stock on Feb 20 ’25. The stock was bought for $110,096 at an average price of $55.05. Upon completion of the transaction, the Chief Executive Officer now directly owns 104,626 shares in the company, valued at $5.21 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Feb 14 ’25, EVP,Chief Med.Offr.,Drug Dev. Hirawat Samit bought 1,823 shares of the business’s stock. A total of $100,000 was incurred on buying the stock at an average price of $54.84. This leaves the insider owning 63,932 shares of the company worth $3.19 million. A total of 0.08% of the company’s stock is owned by insiders.
During the past 12 months, Bristol-Myers Squibb Co has had a low of $39.35 and a high of $63.33. As of last week, the company has a debt-to-equity ratio of 3.13, a current ratio of 1.25, and a quick ratio of 1.15. The fifty day moving average price for BMY is $56.9896 and a two-hundred day moving average price translates $53.73935 for the stock.
The latest earnings results from Bristol-Myers Squibb Co (NYSE: BMY) was released for 2024-12-31. The net profit margin was -18.53% and return on equity was -39.10% for BMY. The company reported revenue of $12.34 billion for the quarter, compared to $11.48 billion a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 7.54 percent.
